These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 29753401)

  • 1. Vitamin D and Calcimimetics in Cardiovascular Disease.
    Lim K; Hamano T; Thadhani R
    Semin Nephrol; 2018 May; 38(3):251-266. PubMed ID: 29753401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.
    Hu P; Xuan Q; Hu B; Lu L; Wang J; Qin YH
    Int J Biol Sci; 2012; 8(5):663-71. PubMed ID: 22606047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of cinacalcet on vascular calcification].
    Yokoyama K
    Clin Calcium; 2015 May; 25(5):729-36. PubMed ID: 25926577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease.
    Khouzam N; Wesseling-Perry K
    Pediatr Nephrol; 2019 Jan; 34(1):1-10. PubMed ID: 28939921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease.
    Torres PA; De Broe M
    Kidney Int; 2012 Jul; 82(1):19-25. PubMed ID: 22437409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
    Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
    G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?
    Levin A; Li YC
    Kidney Int; 2005 Nov; 68(5):1973-81. PubMed ID: 16221197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
    Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
    Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of mineral and bone disorder in chronic kidney disease: quo vadis?
    Nakai K; Komaba H; Fukagawa M
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S2-6. PubMed ID: 19765254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hyperphosphatemia-mediated vascular calcification in cardiovascular outcomes and its management: a review.
    Latif F; Khalid MM; Khan F; Omar Z; Ali FA
    J Cardiovasc Med (Hagerstown); 2013 Jun; 14(6):410-5. PubMed ID: 23392553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into the impact of vitamin D on cardiovascular outcomes in chronic kidney disease.
    Junarta J; Jha V; Banerjee D
    Nephrology (Carlton); 2019 Aug; 24(8):781-790. PubMed ID: 30684283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet: will it play a role in reducing cardiovascular events?
    Karohl C; Raggi P
    Future Cardiol; 2012 May; 8(3):357-70. PubMed ID: 22420327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vitamin D deficiency and cardiovascular diseases].
    Mascitelli L; Goldstein MR; Pezzetta F
    Recenti Prog Med; 2010 May; 101(5):202-11. PubMed ID: 20590017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D and Cardiovascular Disease: Controversy Unresolved.
    Al Mheid I; Quyyumi AA
    J Am Coll Cardiol; 2017 Jul; 70(1):89-100. PubMed ID: 28662812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
    Drüeke TB; Ritz E
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
    Fukagawa M; Komaba H; Kakuta T
    Expert Opin Pharmacother; 2013 May; 14(7):863-71. PubMed ID: 23521343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D and Cardiovascular Complications of CKD: What's Next?
    Banerjee D; Jha V
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):932-934. PubMed ID: 31064752
    [No Abstract]   [Full Text] [Related]  

  • 19. Vitamin D and cardiovascular disease: is the evidence solid?
    Al Mheid I; Patel RS; Tangpricha V; Quyyumi AA
    Eur Heart J; 2013 Dec; 34(48):3691-8. PubMed ID: 23751422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D and cardiovascular disease risk.
    Michos ED; Melamed ML
    Curr Opin Clin Nutr Metab Care; 2008 Jan; 11(1):7-12. PubMed ID: 18090651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.